title: Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand.
abstract: The ligand for flt-3 (FLT3L) exhibits striking structural homology with stem cell factor (SCF) and monocyte colony-stimulating factor (M-CSF) and also acts in synergy with a range of other hematopoietic growth factors (HGF). In this study, we show that FLT3L responsive hematopoietic progenitor cells (HPC) are CD34+CD38-, rhodamine 123dull, and hydroperoxycyclophosphamide (4-HC) resistant. To investigate the basis for the capacity of FLT3L to augment the de novo generation of myeloid progenitors from CD34+CD38- cells, single bone marrow CD34+CD38- cells were sorted into Terasaki wells containing serum-free medium supplemented with interleukin-3 (IL-3), IL-6, granulocyte colony-stimulating factor (G-CSF), SCF (4 HGF) +/- FLT3L. Under these conditions, FLT3L recruited approximately twofold more CD34+CD38- cells into division than 4 HGF alone. The enhanced proliferative response to FLT3L was evident by day 3 and was maintained at all subsequent time points examined. In accord with these findings, we also show that transduction of CD34+CD38- cells with the LAPSN retrovirus is enhanced by FLT3L. The results of these experiments therefore indicate that increased recruitment of primitive HPC into cell cycle underlies the ex vivo expansion potential of FLT3L and also its ability to improve retroviral transduction of HPC.
authors.affiliation: Matthew Roberts Laboratory, Haematology Division, Institute of Medical and Veterinary Science, Adelaide, South Australia.
authors.forename: D N
authors.initials: DN
authors.lastname: Haylock
authors.forename: M J
authors.initials: MJ
authors.lastname: Horsfall
authors.forename: T L
authors.initials: TL
authors.lastname: Dowse
authors.forename: H S
authors.initials: HS
authors.lastname: Ramshaw
authors.forename: S
authors.initials: S
authors.lastname: Niutta
authors.forename: S
authors.initials: S
authors.lastname: Protopsaltis
authors.forename: L
authors.initials: L
authors.lastname: Peng
authors.forename: C
authors.initials: C
authors.lastname: Burrell
authors.forename: I
authors.initials: I
authors.lastname: Rappold
authors.forename: H J
authors.initials: HJ
authors.lastname: Buhring
authors.forename: P J
authors.initials: PJ
authors.lastname: Simmons
mesh_terms: D036541:ADP-ribosyl Cyclase; D051997:ADP-ribosyl Cyclase 1; D000328:Adult; D015703:Antigens, CD; D018952:Antigens, CD34 / Q000032:analysis; D000943:Antigens, Differentiation / Q000032:analysis; D001854:Bone Marrow Cells; D002453:Cell Cycle; D002469:Cell Separation; D002478:Cells, Cultured; D004920:Erythropoiesis; D005434:Flow Cytometry; D006410:Hematopoiesis; D016298:Hematopoietic Cell Growth Factors / Q000502:physiology; D006412:Hematopoietic Stem Cells / Q000166:cytology* / Q000502:physiology; D006801:Humans; D016130:Immunophenotyping; D008562:Membrane Glycoproteins; D008565:Membrane Proteins / Q000502:physiology*; D009244:NAD+ Nucleosidase / Q000032:analysis; D011518:Proto-Oncogene Proteins / Q000502:physiology*; D020794:Receptor Protein-Tyrosine Kinases / Q000502:physiology*; D012190:Retroviridae / Q000235:genetics; D014161:Transduction, Genetic; D051941:fms-Like Tyrosine Kinase 3
chemical_list: D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D016298:Hematopoietic Cell Growth Factors; D008562:Membrane Glycoproteins; D008565:Membrane Proteins; D011518:Proto-Oncogene Proteins; C084881:flt3 ligand protein; C497970:FLT3 protein, human; D020794:Receptor Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3; D036541:ADP-ribosyl Cyclase; C498154:CD38 protein, human; D009244:NAD+ Nucleosidase; D051997:ADP-ribosyl Cyclase 1